Management of Multivessel Coronary Disease in ST-segment Elevation Myocardial Infarction

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiovascular Research

Background:

• ST-segment elevation myocardial infarction (STEMI) treatment typically involves primary percutaneous coronary intervention (PCI) of the infarct-related artery (IRA).
• Multivessel coronary artery disease (CAD) is present in up to 40% of STEMI patients.
• Previous guidelines recommended treating only the IRA lesion, based on observational data.

Purpose of the Study:

• To evaluate the clinical outcomes of complete revascularization versus IRA-only treatment in STEMI patients with multivessel CAD.
• To assess the impact of treating non-infarct-related artery (N-IRA) lesions on major adverse cardiovascular events (MACE).

Main Methods:

• Review of recent randomized controlled trials (RCTs) comparing complete revascularization strategies with IRA-only PCI in STEMI patients.
• Analysis of MACE rates, including death and myocardial infarction (MI), as primary endpoints.
• Consideration of factors like timing of N-IRA intervention and guidance by fractional flow reserve (FFR) or intravascular imaging.

Main Results:

• Recent RCTs indicate improved clinical outcomes and lower MACE rates with complete revascularization (either at index PPCI or during admission).
• These findings challenge the traditional approach of solely treating the IRA in STEMI patients with multivessel disease.
• Further research is needed to address optimal timing, guidance techniques, and hard clinical endpoint reductions for N-IRA interventions.

Conclusions:

• Current guidelines for N-IRA lesion treatment in STEMI patients with multivessel disease may require reconsideration.
• Clinicians must weigh the benefits of complete revascularization against potential risks based on available evidence.
• Future trials are essential to definitively establish the role and optimal strategy for complete revascularization in STEMI.